arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round

ROTTERDAM, the Netherlands and GHENT, Belgium, December 1, 2011 /PRNewswire/ –

Funds will be Used to Progress Differentiated Therapeutic Antibody Programs into Clinical Development

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal…

Popularity: 2% [?]

Share this Post:
Digg Google Bookmarks reddit Mixx StumbleUpon Technorati Yahoo! Buzz DesignFloat Delicious BlinkList Furl

No Responses to “arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round”

Leave a Reply:

Name (required):
Mail (will not be published) (required):
Website:
Comment (required):
XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Get Adobe Flash playerPlugin by wpburn.com wordpress themes